Biotech Values

[DewDiligence]

RVNC—If you’re in for a few years, I think you’ll do very well indeed. In 4Q15, Botox alone sold at an annualized rate of $2.6B, and Botox is not the entire toxin market.

RVNC doesn’t need to vanquish Botox to be enormously successful—it merely has to capture a respectable share of the toxin market, which it ought to be able to do, barring some kind of unexpected safety problem in phase-3 trials.